PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2019; 79(06): 618-625
DOI: 10.1055/a-0880-9295
GebFra Science
Review/Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Trastuzumab in der Behandlung schwangerer Mammakarzinompatientinnen – ein Literaturüberblick

Artikel in mehreren Sprachen: English | deutsch
Sophia S. Goller
Universitätsklinikum Jena, Klinik für Geburtsmedizin, Placenta-Labor, Jena, Germany
,
Udo R. Markert
Universitätsklinikum Jena, Klinik für Geburtsmedizin, Placenta-Labor, Jena, Germany
,
Karolin Fröhlich
Universitätsklinikum Jena, Klinik für Geburtsmedizin, Placenta-Labor, Jena, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 29. Juli 2018
revised 08. Februar 2019

accepted 20. März 2019

Publikationsdatum:
14. Juni 2019 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Das Mammakarzinom gehört zu den am häufigsten in der Schwangerschaft auftretenden Malignomen. Da Frauen zunehmend erst in fortgeschrittenem Alter gebären, ist anzunehmen, dass die Inzidenz schwangerschaftsassoziierter Mammakarzinome zukünftig weiter steigen wird. Aufgrund schwangerschaftsbedingter Veränderungen und zurückhaltender Diagnostik kommt es häufig dazu, dass diese Karzinome erst in fortgeschrittenen Stadien detektiert werden und somit meist einer systemischen adjuvanten Therapie bedürfen. Verfügbare Daten bezüglich des optimalen chemotherapeutischen Managements sind limitiert. Insbesondere zur Anwendung des Target-Agents Trastuzumab, welches in der Therapie des HER2-überexprimierenden Mammakarzinoms der nichtschwangeren Frau einen entscheidenden Beitrag zur Verbesserung der Prognose leisten konnte, fehlen dezidierte Informationen bezüglich des Wirk- und Sicherheitsprofils in der Schwangerschaft sowie auch hinsichtlich etwaiger Langzeiteffekte auf das Kind. Innerhalb der derzeitig verfügbaren Literatur konnten 38 Schwangerschaften unter Trastuzumab zur Therapie eines Mammakarzinoms analysiert werden. Es lassen sich hieraus Informationen gewinnen und Rückschlüsse ziehen, die zukünftig die Therapieoptionen der schwangeren Mammakarzinompatientin individualisieren und entscheidend verbessern können.

Schlüsselwörter

Schwangerschaft - Mammakarzinom - Trastuzumab - intrauterine Wachstumsretardierung - Chemotherapie
 

  • References/Literatur

  • 1 Pirvulescu C, Mau C, Schultz H. et al. Breast Cancer during Pregnancy: An Interdisciplinary Approach in Our Institution. Breast Care (Basel) 2012; 7: 311-314
    CrossrefPubMedSuche in Google Scholar
  • 2 Stensheim H, Moller B, van Dijk T. et al. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009; 27: 45-51
    CrossrefPubMedSuche in Google Scholar
  • 3 Vetter G, Zimmermann F, Bruder E. et al. Aggressive Breast Cancer during Pregnancy with a Rare Form of Metastasis in the Maternal Placenta. Geburtsh Frauenheilk 2014; 74: 579-582
    Thieme ConnectPubMedSuche in Google Scholar
  • 4 Amant F, Loibl S, Neven P. et al. Breast cancer in pregnancy. Lancet 2012; 379: 570-579
    CrossrefPubMedSuche in Google Scholar
  • 5 Dow KH. Pregnancy and breast cancer. J Obstet Gynecol Neonatal Nurs 2000; 29: 634-640
    CrossrefPubMedSuche in Google Scholar
  • 6 Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist 2002; 7: 279-287
    CrossrefPubMedSuche in Google Scholar
  • 7 Barnes DM, Newman LA. Pregnancy-associated breast cancer: a literature review. Surg Clin North Am 2007; 87: 417-430 x
    CrossrefPubMedSuche in Google Scholar
  • 8 Keinan-Boker L, Lerner-Geva L, Kaufman B. et al. Pregnancy-associated breast cancer. Isr Med Assoc J 2008; 10: 722-727
    PubMedSuche in Google Scholar
  • 9 Loibl S. New Therapeutic Options for Breast Cancer during Pregnancy. Breast Care (Basel) 2008; 3: 171-176
    PubMedSuche in Google Scholar
  • 10 Loibl S. Adjuvant therapy in patients with breast cancer during pregnancy. Cancer Treat Res 2009; 151: 317-328
    PubMedSuche in Google Scholar
  • 11 Asgeirsson KS. Pregnancy-associated breast cancer. Acta Obstet Gynecol Scand 2011; 90: 158-166
    CrossrefPubMedSuche in Google Scholar
  • 12 Salani R, Billingsley CC, Crafton SM. Cancer and pregnancy: an overview for obstetricians and gynecologists. Am J Obstet Gynecol 2014; 211: 7-14
    CrossrefPubMedSuche in Google Scholar
  • 13 Voulgaris E, Pentheroudakis G, Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg Oncol 2011; 20: e175-e185
    CrossrefPubMedSuche in Google Scholar
  • 14 Cardoso F, Loibl S, Pagani O. et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer 2012; 48: 3355-3377
    CrossrefPubMedSuche in Google Scholar
  • 15 Loibl S, Schmidt A, Gentilini O. et al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol 2015; 1: 1145-1153
    CrossrefPubMedSuche in Google Scholar
  • 16 Van Calsteren K, Heyns L, De Smet F. et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 2010; 28: 683-689
    CrossrefPubMedSuche in Google Scholar
  • 17 Rich TA, Woodson AH, Litton J. et al. Hereditary breast cancer syndromes and genetic testing. J Surg Oncol 2015; 111: 66-80
    CrossrefPubMedSuche in Google Scholar
  • 18 Sheikh A, Hussain SA, Ghori Q. et al. The spectrum of genetic mutations in breast cancer. Asian Pac J Cancer Prev 2015; 16: 2177-2185
    CrossrefPubMedSuche in Google Scholar
  • 19 Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg 2003; 138: 91-98 discussion 99
    PubMedSuche in Google Scholar
  • 20 Madaras L, Kovacs KA, Szasz AM. et al. Clinicopathological features and prognosis of pregnancy associated breast cancer – a matched case control study. Pathol Oncol Res 2014; 20: 581-590
    CrossrefPubMedSuche in Google Scholar
  • 21 Pavlidis N, Pentheroudakis G. The pregnant mother with breast cancer: diagnostic and therapeutic management. Cancer Treat Rev 2005; 31: 439-447
    CrossrefPubMedSuche in Google Scholar
  • 22 Loibl S, Han SN, Amant F. Being Pregnant and Diagnosed with Breast Cancer. Breast Care (Basel) 2012; 7: 204-209
    CrossrefPubMedSuche in Google Scholar
  • 23 Amant F, Deckers S, Van Calsteren K. et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer 2010; 46: 3158-3168
    CrossrefPubMedSuche in Google Scholar
  • 24 Zemlickis D, Lishner M, Degendorfer P. et al. Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol 1992; 166: 781-787
    CrossrefPubMedSuche in Google Scholar
  • 25 Froehlich K, Stensheim H, Markert UR. et al. Breast carcinoma in pregnancy with spheroid-like placental metastases-a case report. APMIS 2018; 126: 448-452
    CrossrefPubMedSuche in Google Scholar
  • 26 Molckovsky A, Madarnas Y. Breast cancer in pregnancy: a literature review. Breast Cancer Res Treat 2008; 108: 333-338
    CrossrefPubMedSuche in Google Scholar
  • 27 Puckridge PJ, Saunders CM, Ives AD. et al. Breast cancer and pregnancy: a diagnostic and management dilemma. ANZ J Surg 2003; 73: 500-503
    CrossrefPubMedSuche in Google Scholar
  • 28 Aebi S, Loibl S. Breast cancer during pregnancy: medical therapy and prognosis. Recent Results Cancer Res 2008; 178: 45-55
    PubMedSuche in Google Scholar
  • 29 Halaska MJ, Pentheroudakis G, Strnad P. et al. Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study. Breast J 2009; 15: 461-467
    CrossrefPubMedSuche in Google Scholar
  • 30 Cardonick E, Dougherty R, Grana G. et al. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J 2010; 16: 76-82
    CrossrefPubMedSuche in Google Scholar
  • 31 Nami B, Maadi H, Wang Z. Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. Cancers (Basel) 2018;
    CrossrefPubMedSuche in Google Scholar
  • 32 Slamon DJ, Leyland-Jones B, Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
    CrossrefPubMedSuche in Google Scholar
  • 33 Paik S, Bryant J, Tan-Chiu E. et al. Real-world performance of HER2 testing–National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002; 94: 852-854
    CrossrefPubMedSuche in Google Scholar
  • 34 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1, 2018. AWMF Registernummer: 032-045OL. Online: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ last access: 28.05.2018
    PubMed
  • 35 Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27: 5838-5847
    CrossrefPubMedSuche in Google Scholar
  • 36 Fiszman GL, Jasnis MA. Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. Int J Breast Cancer 2011; 2011: 352182
    PubMedSuche in Google Scholar
  • 37 Nuti M, Bellati F, Visconti V. et al. Immune effects of trastuzumab. J Cancer 2011; 2: 317-323
    CrossrefPubMedSuche in Google Scholar
  • 38 Duong MN, Cleret A, Matera EL. et al. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res 2015; 17: 57
    CrossrefPubMedSuche in Google Scholar
  • 39 Maadi H, Nami B, Tong J. et al. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. BMC Cancer 2018; 18: 238
    CrossrefPubMedSuche in Google Scholar
  • 40 Niikura N, Liu J, Hayashi N. et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012; 30: 593-599
    CrossrefPubMedSuche in Google Scholar
  • 41 Franklin MC, Carey KD, Vajdos FF. et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5: 317-328
    CrossrefPubMedSuche in Google Scholar
  • 42 Baselga J, Cortes J, Kim SB. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
    CrossrefPubMedSuche in Google Scholar
  • 43 Gianni L, Pienkowski T, Im YH. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32
    CrossrefPubMedSuche in Google Scholar
  • 44 Lambertini M, Peccatori FA, Azim jr. HA. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev 2015; 41: 301-309
    CrossrefPubMedSuche in Google Scholar
  • 45 Wong Y, Raghavendra AS, Hatzis C. et al. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist 2019; 24: 313-318 doi:10.1634/theoncologist.2018-0213
    CrossrefPubMedSuche in Google Scholar
  • 46 Wolff AC, Hammond ME, Hicks DG. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013
    CrossrefPubMedSuche in Google Scholar
  • 47 Niikura N, Tomotaki A, Miyata H. et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol 2016; 27: 480-487
    CrossrefPubMedSuche in Google Scholar
  • 48 Azim jr. HA, Metzger-Filho O, de Azambuja E. et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat 2012; 133: 387-391
    CrossrefPubMedSuche in Google Scholar
  • 49 Petrek JA, Dukoff R, Rogatko A. Prognosis of pregnancy-associated breast cancer. Cancer 1991; 67: 869-872
    CrossrefPubMedSuche in Google Scholar
  • 50 Amant F, Vandenbroucke T, Verheecke M. et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med 2015; 373: 1824-1834
    CrossrefPubMedSuche in Google Scholar
  • 51 Shlensky V, Hallmeyer S, Juarez L. et al. Management of Breast Cancer during Pregnancy: Are We Compliant with Current Guidelines?. AJP Rep 2017; 7: e39-e43
    Thieme ConnectPubMedSuche in Google Scholar
  • 52 Shen Y, Fujii T, Ueno NT. et al. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat 2018;
    CrossrefPubMedSuche in Google Scholar
  • 53 Niraula S, Gyawali B. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2018;
    CrossrefPubMedSuche in Google Scholar
  • 54 Poulsen MS, Rytting E, Mose T. et al. Modeling placental transport: correlation of in vitro BeWo cell permeability and ex vivo human placental perfusion. Toxicol In Vitro 2009; 23: 1380-1386
    CrossrefPubMedSuche in Google Scholar
  • 55 Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet 1995; 28: 235-269
    CrossrefPubMedSuche in Google Scholar
  • 56 Audus KL. Controlling drug delivery across the placenta. Eur J Pharm Sci 1999; 8: 161-165
    CrossrefPubMedSuche in Google Scholar
  • 57 Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43: 487-514
    CrossrefPubMedSuche in Google Scholar
  • 58 Robinson NR, Atkinson DE, Jones CJ. et al. Permeability of the near-term rat placenta to hydrophilic solutes. Placenta 1988; 9: 361-372
    CrossrefPubMedSuche in Google Scholar
  • 59 Sibley CP. Review article: mechanisms of ion transfer by the rat placenta: a model for the human placenta?. Placenta 1994; 15: 675-691
    CrossrefPubMedSuche in Google Scholar
  • 60 St-Pierre MV, Ugele B, Gambling L. et al. Mechanisms of drug transfer across the human placenta-a workshop report. Placenta 2002; 23 (Suppl. A) S159-S164
    CrossrefPubMedSuche in Google Scholar
  • 61 Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997; 33: 328-343
    CrossrefPubMedSuche in Google Scholar
  • 62 Juchau MR. Bioactivation in chemical teratogenesis. Annu Rev Pharmacol Toxicol 1989; 29: 165-187
    CrossrefPubMedSuche in Google Scholar
  • 63 van der Aa EM, Peereboom-Stegeman JH, Noordhoek J. et al. Mechanisms of drug transfer across the human placenta. Pharm World Sci 1998; 20: 139-148
    CrossrefPubMedSuche in Google Scholar
  • 64 Wong WM. Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer. Cancer Pract 1999; 7: 48-50
    CrossrefPubMedSuche in Google Scholar
  • 65 Saji F, Samejima Y, Kamiura S. et al. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod 1999; 4: 81-89
    CrossrefPubMedSuche in Google Scholar
  • 66 Takizawa T, Anderson CL, Robinson JM. A novel Fc gamma R-defined, IgG-containing organelle in placental endothelium. J Immunol 2005; 175: 2331-2339
    CrossrefPubMedSuche in Google Scholar
  • 67 Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 2009; 86: 328-344
    CrossrefPubMedSuche in Google Scholar
  • 68 Sekar R, Stone PR. Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol 2007; 110: 507-510
    CrossrefPubMedSuche in Google Scholar
  • 69 Chailler P, Briere N. Mitogenic effects of EGF/TGF alpha and immunolocalization of cognate receptors in human fetal kidneys. Biofactors 1998; 7: 323-335
    CrossrefPubMedSuche in Google Scholar
  • 70 Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5: 953-962
    PubMedSuche in Google Scholar
  • 71 Robinson AA, Watson WJ, Leslie KK. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol 2007; 8: 738-743
    CrossrefPubMedSuche in Google Scholar
  • 72 Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric 2008; 11 (Suppl. 01) 47-58
    CrossrefPubMedSuche in Google Scholar
  • 73 Pant S, Landon MB, Blumenfeld M. et al. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 2008; 26: 1567-1569
    CrossrefPubMedSuche in Google Scholar
  • 74 Meattini I, Curigliano G, Terziani F. et al. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. Med Oncol 2017; 34: 75
    CrossrefPubMedSuche in Google Scholar
  • 75 Fanale MA, Uyei AR, Theriault RL. et al. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 2005; 6: 354-356
    CrossrefPubMedSuche in Google Scholar
  • 76 Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 2005; 105: 642-643
    CrossrefPubMedSuche in Google Scholar
  • 77 Waterston AM, Graham J. Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol 2006; 24: 321-322
    CrossrefPubMedSuche in Google Scholar
  • 78 Bader AA, Schlembach D, Tamussino KF. et al. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 2007; 8: 79-81
    CrossrefPubMedSuche in Google Scholar
  • 79 Shrim A, Garcia-Bournissen F, Maxwell C. et al. Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy–Case report and updated literature review. Reprod Toxicol 2007; 23: 611-613
    CrossrefPubMedSuche in Google Scholar
  • 80 Berveiller P, Mir O, Sauvanet E. et al. Ectopic pregnancy in a breast cancer patient receiving trastuzumab. Reprod Toxicol 2008; 25: 286-288
    CrossrefPubMedSuche in Google Scholar
  • 81 Weber-Schoendorfer C, Schaefer C. Untitled. Reprod Toxicol 2008; 25: 390-391
    CrossrefPubMedSuche in Google Scholar
  • 82 Witzel ID, Muller V, Harps E. et al. Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 2008; 19: 191-192
    PubMedSuche in Google Scholar
  • 83 Azim jr. HA, Peccatori FA, Liptrott SJ. et al. Breast cancer and pregnancy: how safe is trastuzumab?. Nat Rev Clin Oncol 2009; 6: 367-370
    PubMedSuche in Google Scholar
  • 84 Beale JM, Tuohy J, McDowell SJ. Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am J Obstet Gynecol 2009; 201: e13-e14
    PubMedSuche in Google Scholar
  • 85 Goodyer MJ, Ismail JR, OʼReilly SP. et al. Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J 2009; 2: 9329
    CrossrefPubMedSuche in Google Scholar
  • 86 Warraich Q, Smith N. Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J Obstet Gynaecol 2009; 29: 147-148
    CrossrefPubMedSuche in Google Scholar
  • 87 Roberts NJ, Auld BJ. Trastuzamab (Herceptin)-related cardiotoxicity in pregnancy. J R Soc Med 2010; 103: 157-159
    CrossrefPubMedSuche in Google Scholar
  • 88 Gottschalk I, Berg C, Harbeck N. et al. Fetal Renal Insufficiency Following Trastuzumab Treatment for Breast Cancer in Pregnancy: Case Report und Review of the Current Literature. Breast Care (Basel) 2011; 6: 475-478
    CrossrefPubMedSuche in Google Scholar
  • 89 Mandrawa CL, Stewart J, Fabinyi GC. et al. A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Aust N Z J Obstet Gynaecol 2011; 51: 372-376
    CrossrefPubMedSuche in Google Scholar
  • 90 El-Safadi S, Wuesten O, Muenstedt K. Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: a case report and review of the literature. J Obstet Gynaecol Res 2012; 38: 589-592
    CrossrefPubMedSuche in Google Scholar
  • 91 Gupta S, Jain P, McDunn S. Breast cancer with brain metastases in pregnancy. J Community Support Oncol 2014; 12: 378-380
    PubMedSuche in Google Scholar
  • 92 Rasenack R, Gaupp N, Rautenberg B. et al. [Case Report on Treatment of Metastatic Breast Cancer with Trastuzumab during Pregnancy]. Z Geburtshilfe Neonatol 2016; 220: 81-83
    Thieme ConnectPubMedSuche in Google Scholar
  • 93 Andrade JM, Brito LG, Moises EC. et al. Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up. Anticancer Drugs 2016; 27: 369-372
    CrossrefPubMedSuche in Google Scholar